リボミック
4591
東証グロース
医薬品
リボミックの決算推移
損益計算書
(単位:百万円)
2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | |
---|---|---|---|---|---|---|---|---|---|---|
売上高 | 479 | 121 | 93 | 64 | 7 | 121 | 91 | 80 | 65 | N/A |
売上原価 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
売上総利益 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
販管費 | 190 | 219 | 269 | 300 | 323 | 362 | 374 | 346 | 360 | 351 |
営業利益 | 6 | -533 | -786 | -900 | -929 | -915 | -1,240 | -1,749 | -1,787 | -1,117 |
営業外収益 | 34 | 210 | 127 | 156 | 105 | 77 | 84 | 115 | 147 | 137 |
営業外費用 | 27 | 0 | 0 | 7 | 11 | 16 | 29 | 2 | 10 | 3 |
経常利益 | 13 | -323 | -659 | -752 | -836 | -854 | -1,185 | -1,636 | -1,650 | -983 |
特別利益 | N/A | N/A | 13 | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
特別損失 | 1 | N/A | N/A | 0 | 0 | N/A | 0 | 48 | 3 | 40 |
当期純利益 | 10 | -324 | -647 | -754 | -837 | -856 | -1,188 | -1,685 | -1,654 | -1,025 |
貸借対照表
(単位:百万円)
2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | |
---|---|---|---|---|---|---|---|---|---|---|
資産 | 3,419 | 3,183 | 2,495 | 2,326 | 2,569 | 2,269 | 6,119 | 4,954 | 4,583 | 3,547 |
流動資産 | 3,387 | 3,112 | 2,433 | 2,240 | 2,502 | 2,175 | 6,050 | 4,908 | 4,542 | 3,506 |
現金及び預金 | 3,337 | 1,860 | 1,783 | 1,580 | 1,413 | 1,601 | 3,338 | 2,901 | 2,825 | 2,099 |
売上債権 | 31 | N/A | 2 | N/A | N/A | 108 | N/A | N/A | N/A | N/A |
棚卸資産 | 1 | 5 | 6 | 3 | 8 | 6 | 3 | 2 | 2 | 2 |
固定資産 | 32 | 70 | 62 | 86 | 67 | 94 | 69 | 46 | 41 | 40 |
負債 | 156 | 144 | 57 | 99 | 1,086 | 88 | 116 | 260 | 199 | 155 |
流動負債 | 156 | 144 | 57 | 99 | 86 | 88 | 116 | 260 | 199 | 155 |
仕入債務 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
固定負債 | N/A | N/A | N/A | N/A | 1,000 | N/A | N/A | N/A | N/A | N/A |
純資産 | 3,262 | 3,039 | 2,438 | 2,227 | 1,483 | 2,180 | 6,002 | 4,693 | 4,384 | 3,391 |
利益剰余金 | -2,455 | -2,778 | -3,425 | -4,178 | -5,014 | -5,869 | -7,056 | -1,685 | -1,654 | -1,025 |
自己株式 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | -1 |